Aplastic Anemia

Dr. Erba entered medical school for the sole purpose of learning more about human diseases, so that he could focus his laboratory efforts on improving the human condition. However, he was surprised to find himself drawn to clinical care. He cares for people afflicted by acute leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. In this role, Dr. Erba has had the privilege of treating people facing life-threatening illnesses. He strives to gain the trust of each of his patients, so that he can help them make difficult treatment decisions. He engages in clinical research

Dr. DiNardo is a clinical researcher with a specialized focus on prognostication and personalized therapeutics for patients with myeloid malignancies. She has completed formal training in epidemiology and biostatistics, with a Master’s of Science in Clinical Epidemiology obtained in June 2012. Her thesis involved an analysis of isocitrate dehydrogenase (IDH) mutations, serum 2-hydroxyglutarate (2HG) levels, and patient outcomes in AML, performed in collaboration with the Eastern Cooperative Oncology Group (ECOG). Dr. DiNardo is the primary investigator of multiple novel IDH1 or IDH2-targeted

My research interest is focused on the development of novel therapeutic agents for the treatment of hematological malignancies. Towards this aim, I am serving in three different leadership positions: 1) I am the director of the UNM Bone Marrow Transplant and Cell Therapy Program, which has brought autologous hematopoietic stem cell transplant technology to New Mexico, with the intent of introducing allogeneic stem cell transplant and both CAR-T therapy in the near future. Our program is currently undergoing FACT accreditation to further this aim. 2) I am the leader of the Hematology Clinical